DUBAI, U.A.E, Sept. 17, 2020 /PRNewswire/ -- The global pharmaceutical plastic packaging market will grow at a CAGR of 6.1% during the forecast period, 2020-2030. The growth is anticipated to be fuelled by increasing instances of deadly disease outbreaks such as H1N1, COVID-19. This prompts an increase in pharmaceutical plastic packaging demand. Furthermore, developed regions are foreseeing a proliferation of their geriatric populace.
The global pharmaceutical company and service partner Inceptua Group (previously Multipharma GmbH) and Bendalis GmbH – German manufacturer of generic oncology drugs and special therapeutic agents, today announce the signing of an exclusive clinical trial supply agreement for oncology generics.
Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced it has entered into a Feasibility and Option agreement with Novartis Pharmaceuticals to explore using the Accordion Pill platform for a proprietary Novartis compound. The details of the therapeutic area or specific compound were not released. Following potentially successful feasibility studies including a Phase 1 PK study, Novartis has the option to enter into negotiations with respect to a potential licensing agreement for employing Intec Pharma Accordion Pill™ technology.